6660 Stock Overview
Researches, develops, manufactures, and commercializes of vaccine products for human use in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
AIM Vaccine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.13 |
| 52 Week High | HK$15.48 |
| 52 Week Low | HK$3.95 |
| Beta | -0.00055 |
| 1 Month Change | -16.49% |
| 3 Month Change | 7.17% |
| 1 Year Change | -23.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6660 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 0.5% | -1.2% | 1.9% |
| 1Y | -23.8% | -11.8% | 18.1% |
Return vs Industry: 6660 underperformed the Hong Kong Biotechs industry which returned -9.2% over the past year.
Return vs Market: 6660 underperformed the Hong Kong Market which returned 20.6% over the past year.
Price Volatility
| 6660 volatility | |
|---|---|
| 6660 Average Weekly Movement | 28.8% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in HK Market | 18.7% |
| 10% least volatile stocks in HK Market | 4.0% |
Stable Share Price: 6660's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6660's weekly volatility has increased from 16% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,557 | Yan Zhou | www.aimbio.com |
AIM Vaccine Co., Ltd. researches, develops, manufactures, and commercializes of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, that is in phase IV clinical trials indicated for meningococcal disease 13-Valent pneumonia Conjugate and 23-valent pneumonia Polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine which is in phase III clinical trials to treat COVID-19 infection. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, that is in phase II trials for the treatment of meningococcal disease; EV71-CA16 Bivalent HFMD vaccine.
AIM Vaccine Co., Ltd. Fundamentals Summary
| 6660 fundamental statistics | |
|---|---|
| Market cap | HK$7.42b |
| Earnings (TTM) | -HK$1.27b |
| Revenue (TTM) | HK$1.26b |
5.9x
P/S Ratio-5.9x
P/E RatioIs 6660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6660 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.18b |
| Cost of Revenue | CN¥1.84b |
| Gross Profit | -CN¥655.57m |
| Other Expenses | CN¥534.32m |
| Earnings | -CN¥1.19b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | -55.36% |
| Net Profit Margin | -100.48% |
| Debt/Equity Ratio | 51.8% |
How did 6660 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 00:55 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AIM Vaccine Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tony Ren | Macquarie Research |